Search results
Amgen Sweetens Full-Year Outlook After Narrowly Beating Third-Quarter Forecasts
Investor's Business Daily· 2 years agoAmgen stock popped Friday after the drugmaker sweetened its 2022 outlook following a third-quarter...
Amgen Tumbles After Scrapping A $900 Million Prostate Cancer Drug
Investor's Business Daily· 6 months agoAmgen handily beat Wall Street's earnings forecasts Tuesday, but Amgen stock tumbled after the...
These Drugs Are the New First Line of Defense Against Migraine
Verywell Health via Yahoo News· 1 month agoIllustration by Julie Bang for Verywell Health Fact checked by Nick Blackmer Key Takeaways CGRP...
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
Zacks via Yahoo Finance· 2 years agoWith the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only...
Why Is Amgen (AMGN) Down 4.2% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 year agoIt has been about a month since the last earnings report for Amgen (AMGN). Shares have lost about...
Amgen Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance· 21 hours agoAmgen Inc (NASDAQ:AMGN) has recently announced a dividend of $2.25 per share, set to be payable on June 7, 2024, with the ex-dividend date on May 16,...
Amgen (AMGN) Valuation: A Comprehensive Analysis of Its Market Value
GuruFocus.com via Yahoo Finance· 7 months agoAs of October 10, 2023, Amgen Inc (NASDAQ:AMGN) experienced a day's loss of -1.02%, with a 3-month...
Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
Zacks via Yahoo Finance· 9 months agoAmgen AMGN reported second-quarter 2023 earnings of $5.00 per share, which beat the Zacks Consensus...
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
Zacks via Yahoo Finance· 1 year agoFor new and old investors, taking full advantage of the stock market and investing with confidence...
Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx
Zacks via Yahoo Finance· 2 years agoAmgen AMGN reported second-quarter 2022 earnings of $4.65 per share, which beat the Zacks Consensus...